Libby Hahn

Libby Hahn serves as Associate Director of Market Research at Cytokinetics since January 2022, focusing on the launch of the cardiovascular heart failure medication omecamtive mecarbil. Prior to this role, Libby held the position of Associate Director of Market Research and Competitive Intelligence at LEO Pharma from February 2021 to January 2022. Libby's extensive experience at Pfizer includes roles as Director of Business Analytics, where leadership contributed to the success of Xeljanz, and Senior Manager positions in Global Early Commercial Development and Inflammation & Immunology, overseeing market research and analytics for various rheumatology products. Libby initiated key research plans during the pre-launch and post-launch phases of Xeljanz and played a pivotal role in the launch strategy for the Prevnar 13 Adult pneumococcal vaccine. Libby Hahn holds a Master of Public Administration from Indiana University Bloomington and a Bachelor of Arts in Economics from Denison University.